Humalog

Humalog is a rapid‑acting insulin analog containing the active ingredient insulin lispro, supplied as an injectable solution for subcutaneous use. While the specific strength may vary by market, the product is formulated for precise glucose control in diabetes management. It is authorized for prescription use within the European Union and belongs to the antidiabetic therapeutic class. Humalog is indicated for type 1 and type 2 diabetes and is administered under supervision.

Humalog is prescribed to improve glycemic control in patients with diabetes when rapid insulin action is required.

- Mealtime (prandial) insulin for type 1 diabetes. - Mealtime (prandial) insulin for type 2 diabetes. - Correction of post‑prandial hyperglycemia. - Use in insulin pump therapy as a rapid‑acting component. - Transition from intravenous to subcutaneous insulin in hospital settings. - Adjunct to basal insulin regimens for tighter overall glucose control. - Used in pediatric patients under specialist guidance when rapid insulin action is needed.

Like other rapid‑acting insulins, Humalog may be associated with a range of adverse reactions, most of which are mild and transient.

Common: - Hypoglycemia, especially if meals are missed or delayed. - Injection‑site pain, redness, or swelling. - Lipodystrophy at repeated injection sites. - Allergic skin reactions such as rash or urticaria.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms. - Anaphylactic reaction, including difficulty breathing or swelling of the face. - Persistent hyperglycemia indicating possible insulin resistance. - Edema or heart failure exacerbation in susceptible patients.

Healthcare providers should evaluate individual risk factors before initiating Humalog and monitor patients regularly during therapy.

- Assess renal and hepatic function, as impairment can alter insulin clearance. - Adjust dose when patients engage in vigorous exercise or change dietary patterns. - Use caution in pregnant or breastfeeding individuals; benefits must outweigh potential risks. - Monitor for signs of hypoglycemia, especially in the elderly or those with limited food intake. - Avoid use in patients with known hypersensitivity to insulin lispro or any excipients. - Consider cardiovascular status, as rapid insulin shifts may affect fluid balance.

Humalog can interact with several medications, affecting glucose levels or insulin action, and should be managed accordingly.

Avoid: - Concurrent use of other rapid‑acting insulins or high‑dose insulin secretagogues without dose adjustment. - Beta‑blockers that mask hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise blood glucose and require higher insulin doses. - Thiazide diuretics, which can reduce insulin sensitivity. - Alcohol consumption, especially in excess, which can cause delayed hypoglycemia.